

Cover Story
Guest Editorial
By John H. Stewart and Robert A. Winn
Advances in the field of tumor immunotherapy have given great hope for those treating cancer. We are in an era of unprecedented achievements, as evidenced by impressive clinical responses in patients treated with adoptive cell therapy and immune checkpoint inhibitors.
By Claire Dietz and Matthew Bin Han Ong
In Brief
Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for May
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - NCAB asks for help from administration as NCI deals with deluge of grant applications
- Trump’s tariffs on generic drugs are “another wrinkle in an already unstable system”
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Mount Sinai oncologist Krystal Cascetta, 40, and her infant daughter die in Somers, NY, home
- Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab















